2 registrations that name shiitake as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
Not yet recruitingNCT07118735
AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy
No phase
National Cheng-Kung University Hospital
About 94 people
Starts Aug 20, 2025 (estimated)
In plain words A study of shiitake in people 20 and older, run by National Cheng-Kung University Hospital. It plans to enroll about 94 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Liver Cancer; Hepatocellular Carcinoma.
1.Liver cancer patient who will receive immunotherapy
2.At least one measurable tumor, according to RECIST version 1.1, that has not been treated with any local procedure.
3.Age >=20 years old.
4.ECOG performance status 0 or 1.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
A standardized extract of cultured Lentinula edodes mycelia (AHCC®); Placebo
Registered summary
This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.
Where, as registered
No US site; Taiwan (1).
Not yet recruitingNCT07479394
Impact of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 4-6 Years Old
Phase 4
Hasanuddin University
About 60 people
Starts Aug 15, 2026 (estimated)
In plain words A Phase 4 study of shiitake in people 4 to 6, run by Hasanuddin University. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 6; healthy volunteers accepted. Conditions: Respiratory Tract Infections (RTI).
Children aged 4-6 years old at the time of enrolment
Good nutritional status with weight-for-height > -2, and height-for-age z-score > -2 based on WHO growth standards
Infants in a group setting (daycare centers).
No congenital disorder
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
a prebiotic, that us a standardized extract of cultured Lentinula edodes mycelia; Placebo (dextrin)
Registered summary
This is a study to evaluate the effects of a prebiotic, AHCC, a standardized extract of cultured Lentinula edodes mycelia, on immunologic markers and the incidence of respiratory tract infections in children.